All In Biotech

Drug Trial Radar · NCT07819188

SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma

A Phase Ib/II Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of SCTB35 in Combination With SCTB41, With or Without Concomitant Chemotherapy, in Patients With Non-Hodgkin's Lymphoma.

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Sep 30, 2028

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Sep 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of SCTB35 and SCTB41 With or Without Chemotherapy in non-Hodgkin's lymphoma patients.

Conditions

  • NHL - Non-Hodgkin's Lymphoma

Interventions

  • SCTB35 injectionDrug

    SCTB35 will be subcutaneously administered at a dose as specified

  • SCTB41Drug

    SCTB41 will be IV administered at a dose as specified

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: dose limited toxicity (DLT)Time frame: Within 28 days of the first administration
  2. Phase 2: Percentage of Participants Achieving Objective Response Rate (ORR)Time frame: Up to approximately 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjing, Tianjing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.